Ghassan K. Abou-Alfa, MD,discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma.
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma (HCC).
The study was conducted in the subgroup of patients with Child-Pugh A and Barcelona Clinical Liver Cancer stage B/C who were previously treated with at least 1 prior systemic therapy.
Tislelizumab achieved durable response in the study and was well-tolerate by patients. According to Abou-Alfa, the data were very encouraging and signal hope for the success of a phase 3 study of tislelizumab, which is ongoing.
0:08 | In brief, we're quite excited that tislelizumab as another anti-PD-1, but with a very important specificity and regard to its mechanisms of action have been evaluated in this phase 2 study and led to the finding of important results, among which is an increase response rate of close to about 13% with importantly, 2 complete responses and 29 partial responses. And if anything, this translated into improvement in outcome, over a medium follow up close to about 9 to 10 months. Median overall survival was 12.4 months and medium progression- free survival was 2.7 months.
0:56 | It is important to note the 1-year overall survival was close to 52%. No doubt that this is very encouraging, especially that the therapy was tolerable. And of course, we look forward for the results of the ongoing randomized phase 3 trial evaluating tislelizumab compared to the standard, sorafenib, as first line therapy for patients with advanced unresectable HCC
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More